Skip to main content

Table 2 Comparison of clinical characteristics at baseline and follow-ups

From: Quantitative assessment of lesion load and efficacy of 3 cycles of albendazole in disseminated cysticercosis: a prospective evaluation

Clinical featuresBaseline (N = 29)1st follow-up (N = 29)2nd follow-up (N = 29)3rd follow-up (N = 29)P value
Seizures (Number of patients)26 (89.7%)13 (44.8%)6 (20.7%)1 (3.4%)< 0.001
Seizures (Number of events)    < 0.001
• Total15864183 
• Median4 (2.5–8.0)0 (0–5.5)0 (0–0)0 (0–0) 
• Maximum15953 
Headache (Number of patients)22 (75.9%)14 (48.3%)10 (34.5%)7 (24.1%)< 0.001
  1. Note: Statistically significant P values have been italicized